Nanoform targets cost leadership for CESS platform as it scales commercial GMP output in Helsinki
Bitget2026/09/22 05:04- Nanoform set out plans to position its CESS technology as a cost leader versus spray-dried amorphous solid dispersions.
- Strategy centers on expanding clinical and commercial GMP CESS capacity in Helsinki to support multi-ton annual production.
- Focus on lowering cost of goods through higher yields, reduced excipient use, simplified downstream processing, lower capital requirements.
- Commercial push targets higher drug loading to cut pill burden while matching or improving bioavailability versus spray-dried ASDs.
- Manufacturing roadmap emphasizes recycled pharmaceutical-grade CO₂ processing to reduce solvent use and improve sustainability economics.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
